Vemurafenib in pediatric patients withBRAFV600Emutated high-grade gliomas

Drug safety evaluation of vemurafenib in the treatment of melanoma

(2013) Kenneth Y Tsai et al.   Expert Opinion On Drug Safety

Brainstem Ganglioglioma Successfully Treated With Vemurafenib

(2013) Sarah Rush et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

(2013) Paolo A. Ascierto et al.   JOURNAL OF CLINICAL ONCOLOGY

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

(2012) J. Haroche et al.   BLOOD

Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation

(2012) Nicole M. Rochet et al.   MAYO CLINIC PROCEEDINGS

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

(2011) Genevieve Schindler et al.   ACTA NEUROPATHOLOGICA

Vemurafenib

(2011) Keith. T Flaherty et al.   NATURE REVIEWS DRUG DISCOVERY

Vemurafenib for Melanoma Metastases to the Brain

(2011) Nicole M. Rochet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

(2010) J. D. Schiffman et al.   CANCER RESEARCH

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE